Compared with standard care alone, outpatient palliative care is associated with benefits among patients with Parkinson disease and related disorders.
The FDA has approved an expanded indication for the Infinity™ Deep Brain Stimulation (DBS) system (Abbott) to include targeting the internal globus pallidus, which may lead to symptom improvement in patients with Parkinson disease.
Among patients with moderately severe Parkinson disease, exploratory biomarkers are altered in response to nilotinib, but the rate of serious adverse events (SAEs) is significantly higher in those receiving nilotinib versus placebo.
Patients with Parkinson disease (PD) who use inappropriate antipsychotics may be at an increased risk for pneumonia compared with patients with PD who use more appropriate atypical antipsychotics.
Published studies that included data on the risk for PD in patients with BD vs the general population without BD were included in a systematic review.
Nourianz is now available as an adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson disease (PD) experiencing “off” episodes.
The Food and Drug Administration (FDA) has issued a warning letter to Curalef Inc. of Wakefield, Massachusetts for illegally selling unapproved cannabidiol (CBD) products online with unsubstantiated health claims.
In patients with Parkinson disease who receive subthalamic nucleus deep brain stimulation, suicide behaviors tend to occur during the first 3 years after the procedure.
International Parkinson’s and Movement Disorder Society released recommendations on clinical screening instruments and rating scales used to measure impulsive and compulsive behaviors in Parkinson disease.
More frequent manic/mixed and depressive episodes were associated with an increased risk for Parkinson disease.